AI assistant
Pyxis Oncology, Inc. — Director's Dealing 2021
Oct 8, 2021
33976_dirs_2021-10-07_d96fd7b6-7429-415f-95aa-4ca15d0b12ff.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Pyxis Oncology, Inc. (PYXS)
CIK: 0001782223
Period of Report: 2021-10-07
Reporting Person: Sullivan Lara (N/A)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 298789 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to buy) | $5.34 | 2031-03-30 | Common Stock (990461) | Direct | |
| Stock Option (Right to buy) | $8.71 | 2031-09-14 | Common Stock (61825) | Direct |
Footnotes
F1: Includes 161,844 shares of restricted stock that are subject to vesting in 26 substantially-equal monthly installments beginning November 2, 2021, subject to the reporting person's continued employment through the applicable vesting date.
F2: These stock options vest in 48 substantially-equal monthly installments beginning January 2, 2020, subject to the reporting person's continued employment through the applicable vesting date.
F3: These stock options vest 25% on the first anniversary of the closing of the Issuer's initial public offering, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.